Vascular Therapies, Inc.

Other

Avi Biopharma, Inc.

Endobar Solutions LLC

Estrogen Vascular Technology, LLC

Sarepta Therapeutics, Inc.

Nicholas N Kipshidze

Sriram S Iyer

Victor V Nikolaychik

Martin B Leon

Jeffrey Warren Moses

Gary Roubin

Patrick L Iversen

Ran Kornowski

Bandula Wijay

Harvinder Sahota

Eran Levit

Gregg W Stone

Gishel New

Jason Rahimzadeh

A suspension of a therapeutic substance (e.g., embolic beads) dispersed within a liquid can be delivered via a catheter by using a bidirectional pump to rapidly draw the mixture of the therapeutic substance and liquid from an external syringe into an internal reservoir, then rapidly push the mixture back out into the external syringe. The rapid operation of the bidirectional pump mixes the two constituents so that the therapeutic substance is temporarily suspended within the liquid. Then, a low-speed pump is used to inject the mixture out via the catheter. In some embodiments, the parameters of the low-speed pump are controlled so that the fluid exiting the catheter will experience laminar flow. When the therapeutic substance comprises embolic beads, this can advantageously prevent reflux of the embolic beads, which can be dangerous.

Dual-pump system for delivering embolic beads or other therapeutic substances into an artery

This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are disclosed.

Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts

Devices and methods for reducing, eliminating, preventing, suppressing, or treating tissue responses to hemostatic devices e.g., biological sealants or vascular procedures are disclosed. The invention employs a combination of resorbable, biocompatible matrix materials and a variety of therapeutic agents, such as antiproliferatives or antibiotics, applied to a vascular puncture or incision to achieve hemostasis following diagnostic or interventional vascular catheterizations and to treat neointimal hyperplasia and stenosis. A matrix of a material such as collagen provides a reservoir of a therapeutic agent such as rapamycin (sirolimus) and its derivatives and analogs for delivery at a tissue site at risk for vasculoproliferation, infection, inflammation, fibrosis or other tissue responses.

Medical implants and methods for regulating the tissue response to vascular closure devices

Administration of a formulation comprising a antirestenotic compound conjugated to a microparticle carrier is effective to inhibit stenosis formation in a blood vessel. Such stenosis typically results, in the absence of treatment, from trauma to a vessel, such as an incision, excessive pressure, an angioplasty procedure and/or stent implantation. The antirestenotic compound is typically an antiproliferative, immunosuppressive, or antiinflammatory drug, such as rapamycin, tacrolimus, paclitaxel, dexamethasone, or an active analog or derivative, an antisense oligonucleotide, or combinations thereof. The microparticle carrier comprises a suspension of gas-filled microbubbles or biocompatible polymeric microparticles, in a pharmaceutically acceptable liquid vehicle, and is effective to deliver the conjugated therapeutic to the site of vessel injury.

Delivery of microparticle-conjugated drugs for inhibition of stenosis

The present invention relates to methods and apparatuses for use in revascularization of damaged areas of myocardium through application of one or more radiation type treatment modalities.

Method and apparatus for increasing angiogenic, growth factor in heart muscle

The method of vascular treatment for restenosis or vulnerable plaque after an invasive procedure, such as for example angioplasty, stenting with or without drug coating, or drug delivery, comprises: inserting a catheter or hollow guide wire to the treatment location; delivering light through the catheter in the wavelength range of about 700&#x2013;2500 nm; and moving the light to treat the affected region.

Electromagnetic photonic catheter for reducing restenosis

A method of treating or preventing vascular disease in a living organism. The method includes delivering an effective amount of a composition including a sex hormone, anti-hormone, sex-hormone agonist, steroid-hormone inhibitor/antagonist (partial or full), selective estrogen receptor modulator (SERM), or a combination thereof, to an affected area of a living organism.

Growing community of inventors

New York, NY, United States of America

Nicholas N Kipshidze